Why this expert has a 'positive long-term view' on the CSL share price

Is there a potential buying opportunity for CSL shares?

| More on:
doctor making thumbs up gesture and holding vial labelled 'covid-19 vaccine' representing covid shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price is holding up against the market sell-off this morning as experts recommend investors buy the shares
  • Medallion Financial Group rates CSL a long-term buy due to new technology and demand for flu vaccines
  • Two other brokers have also reiterated their buy recommendations on the shares last week following a favourable court ruling for the blood donation industry

Our market is in for a rough ride but the weakness could present longer-term investors with a buying opportunity for CSL Limited (ASX: CSL) shares.

Shares in the global biotech slipped 0.1% in early trade before bouncing 0.2% higher at $278.72.

That's a good outcome given that the S&P/ASX 200 Index (ASX: XJO) crashed 1.5% on recession fears.

Why the CSL share price is a long-term buy

The volatility is likely to stay for a while, but that won't change the positive view on the shares from Medallion Financial Group's Jean-Claude Perrottet.

New technology and demand for flu vaccinations are some of the reasons for his "buy" recommendation on the CSL share price, according to The Bull. He said:

Full year results for this blood products company were positive in response to strong demand for flu vaccines, in our view.

CSL is rolling out new technology in the US, which reduces plasma donation procedure times by about 30 per cent. These innovations should improve the collection process and, as a result, we retain a positive long-term view on CSL.

Court ruling gives a secondary boost

He isn't the only one that is bullish on the CSL share price either. This is particularly so after a US District Court for the District of Columbia issued a favourable ruling on blood donations.

The preliminary injection prevents US border officials from enforcing a ban on paid plasma donations from Mexicans that enter the US on USB1/B2non-immigrant visas, noted Morgan Stanley.

US border officials had previously said that such donations were a violation of the terms of the visa.

What is the CSL share price worth?

Morgan Stanley commented:

CSL has 304 centers in the US with ~16 near the US/Mexican Border – which we estimate may have accounted for ~10% of plasma collections. If the US border issue is resolved this would be a clear positive for CSL.

Morgan Stanley has an overweight recommendation on the CSL share price with a price target of $323 a share.

This positive view was echoed by Citigroup, although the broker doesn't think this development has a major impact on CSL.

Citi said:

This is a positive for the industry which has just recently seen plasma collections reach pre-pandemic levels. For CSL the impact will positive, but relatively small.

Nonetheless, Citi is recommending investors buy the CSL share price. Its 12-moth price target is $340 a share.

Motley Fool contributor Brendon Lau has positions in CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A mature age woman with a groovy short haircut and glasses, sits at her computer, pen in hand thinking about information she is seeing on the screen.
Share Market News

ASX shares in April: 8 key takeaways according to Macquarie

Here are eight key takeaways from April, according to a new note from the broker.

Read more »

A shocked man holding some documents in the living room.
Broker Notes

Macquarie's take on Judo Capital shares after suddenly falling 19% yesterday?

Judo Bank was the ASX's top-performing banking stock in 2024.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Broker Notes

5 top ASX stocks to buy in May

These stocks could be quality picks for investors this month according to analysts.

Read more »

Person pressing the sell button on a smartphone.
Broker Notes

Sell alert! 3 ASX shares the brokers are calling time on

Brokers say it's time to hit the sell button on these ASX shares.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Share Market News

What is next for ASX 200 shares after last month's upheaval?

Macquarie reveals its outlook for ASX 200 shares in May in a new research note published today.

Read more »

Happy young couple saving money in piggy bank.
Broker Notes

Invest $500 in these top ASX shares in May

Analysts think these shares could be in the buy zone for the month ahead.

Read more »

Person pointing finger on on an increasing graph which represents a rising share price.
Broker Notes

These ASX 200 shares could rise 30% to 40%

Let's see what analysts are saying about these buy-rated shares.

Read more »